Prevail Therapeutics Announces Investigational New Drug Trial for Parkinson’s Disease

U.S. Food and Drug Administration (FDA) has accepted Prevail’s Investigational New Drug (IND) application for its lead gene therapy program, PR001. PR001 is a potentially disease-modifying, single-dose, AAV9-based gene therapy being developed for the treatment of Parkinson’s disease patients with a GBA1 mutation (PD-GBA). 

Stay in Touch with NGF

Learn about the latest research, news and events.